Background Hepatocellular carcinoma (HCC) is one of the most common malignant solid
tumors. Its incidence is increasing worldwide due to the dissemination of hepatitis B …

Background Programmed cell death protein‐1‐targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …

Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world, with a high
relapse rate. Delayed symptom onset observed in 70-80% of patients leads to diagnosis in …

Hepatocellular carcinoma (HCC) is a heterogeneous malignancy related to diverse
etiological factors. Different oncogenic mechanisms and genetic variations lead to multiple …

Hepatocellular carcinoma (HCC) is the most common primary neoplasia of the liver. There
have been tremendous efforts in the development of therapeutic strategies in the last …

Hepatocellular carcinoma (HCC) is a prevalent and refractory cancer in the world and very
few drugs are available for the disease treatment currently. Programmed cell death protein-1 …

Background The prognosis for advanced Hepatocellular carcinoma (HCC) is still very poor.
Despite initial usefulness of immune checkpoint inhibitor (PD-1), phase 3 trials failed to …

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …

Simple Summary The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is now
a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only …

Simple Summary The cytotoxic T cell response against hepatocellular carcinoma antigens is
exhausted and fails in its task of deleting tumoral cells. These cells are featured by the …